| Monday Breakfast | Tuesday Breakfast |
| Mundipharma | Seqirus |
| Lilly |
Monday 6 April, Morning Session 7:15 - 8:15 am
Perspectives on the use of opioids for pain management and regulatory responses to opioid related harms
Opioid related harms have increased in line with increases in prescribing, specifically for chronic non-cancer pain, precipitating re-evaluation of their role in modern pain management and initiating a range of regulatory responses. The reasons for opioid failure and factors contributing to harm will be examined. Learnings from hospital based audits and the implementation of Victoria's medication monitoring system (Safescript) will be presented. The implications of the pending national opioid reforms on future pain practice will be examined.
Anti-CGRP monoclonal antibodies for migraine – from discovery to clinical practice
Emgality is a CGRP monoclonal antibody that is specifically developed to prevent migraine. Eli Lilly is delighted to bring Emgality to Australian patients for the prevention of migraine. Please join us for this exclusive opportunity to explore real-world experience in treating migraine patients.
Speaker: Professor Paul Rolan (MD FRACP FFPM FFPMANZCA) is a clinical pharmacologist, pharmaceutical physician and pain physician. After obtaining specialist qualifications Paul spent nearly 20 years in the UK in the development of new medicines. He has been Principal Investigator in over 650 clinical research studies and has been an active Consultant, both to the pharmaceutical industry as well as an invited speaker to the FDA. His major clinical and academic interest is in chronic pain and headache, focusing on the development of biomarkers, evaluation of novel therapies and mechanisms of disease.
Tuesday 7 April, Morning Session 7:15 - 8:15 am
Navigating Pain in the Current Opioid Environment
The current opioid environment raises a number of important considerations. What can we learn from the path so far? How can we best manage pain patients and their expectations? What can assist us in the directions we take now and into the future? Dr Hilton Francis will address these issues with an eye to their clinical implications and implementation.
Individual opioids differ in their pharmacology and clinical effects. In the context of rising rates of pharmaceutical opioid use and harms in Australia, population-level data can provide useful insights on differences between opioids. A/ Prof Suzanne Nielsen and Dr Tina Lam have examined the rates and characteristics of ambulance attendances related to extra-medical use of individual pharmaceutical opioids in Victoria. They will present this new information and what it means for the clinician and the community.
Speaker: Dr Hilton Francis is a Senior Consultant Rheumatologist and Pain Specialist who has provided Rheumatology care to patients throughout Tasmania for more than thirty years, and who is currently Director of Pain Service at Royal Hobart Hospital, and an accredited Pain Management Specialist and Rheumatologist at both the Royal Hobart Hospital and Calvary Hospital Hobart.
